(0.13%) 5 161.50 points
(0.11%) 38 874 points
(0.12%) 18 023 points
(0.97%) $78.87
(0.47%) $2.15
(1.00%) $2 331.60
(2.63%) $27.39
(0.52%) $970.30
(0.02%) $0.929
(-0.28%) $10.84
(-0.18%) $0.796
(0.18%) $91.62
@ $13.71
发出时间: 15 Feb 2024 @ 00:10
回报率: 39.68%
上一信号: Feb 13 - 22:37
上一信号:
回报率: -1.15 %
Live Chart Being Loaded With Signals
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally...
Stats | |
---|---|
今日成交量 | 155 159 |
平均成交量 | 135 758 |
市值 | 3.34B |
EPS | $0 ( 2024-02-28 ) |
下一个收益日期 | ( $0 ) 2024-05-22 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 31.92 |
ATR14 | $0.0210 (0.11%) |
音量 相关性
Hutchison China MediTech 相关性 - 货币/商品
Hutchison China MediTech 财务报表
Annual | 2023 |
营收: | $838.00M |
毛利润: | $453.55M (54.12 %) |
EPS: | $0.590 |
FY | 2023 |
营收: | $838.00M |
毛利润: | $453.55M (54.12 %) |
EPS: | $0.590 |
FY | 2022 |
营收: | $426.41M |
毛利润: | $115.31M (27.04 %) |
EPS: | $-2.42 |
FY | 2021 |
营收: | $356.13M |
毛利润: | $97.89M (27.49 %) |
EPS: | $-1.250 |
Financial Reports:
No articles found.
Hutchison China MediTech
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。